Emary W B, Toren P C, Mathews B, Huh K
Drug Metabolism, Nonclinical Pharmacokinetics/Pharmacodynamics, Hoechst Marion Roussel, Kansas City, MO 64134, USA.
Drug Metab Dispos. 1998 Aug;26(8):725-31.
Rifapentine is a cyclopentyl derivative of rifampin under development for the treatment of Mycobacterium tuberculosis and Mycobacterium avium complex infections. These studies were designed to investigate the disposition and biotransformation of single iv and oral doses of 14C-rifapentine in mice, bile duct-cannulated and uncannulated rats, and monkeys. Mass balance studies included 14C analyses of urine, feces, bile, cage wash, carcasses, and cage air collected for up to 120 hr postdose. Separation of radioactive compounds extracted from urine, bile, and feces was conducted using high-performance liquid chromatography and radioisotope detection. The mass spectra of selected chromatographic peaks were obtained. Disposition results were similar for all three species. Less than 5% of the radioactive dose of 14C-rifapentine was recovered in urine, indicating that renal excretion is a minor route of elimination in these species. The major route of elimination of radioactivity was into the feces, where more than 75% of the radioactivity was recovered. Biliary excretion was the major route of elimination of radioactivity in bile duct-cannulated rats dosed either po or IV. Radiochromatograms were similar for fecal samples from animals dosed by IV or orally. Ten regions of radioactivity were observed in mouse and rat fecal sample radiochromatograms, and seven regions of radioactivity were observed in monkey fecal sample radiochromatograms. The most abundant compound identified in feces was usually intact rifapentine (27%-41% of dose in mouse, 3%-35% of dose in rat, and 17%-29% of dose in monkey). Other peaks identified or characterized in feces based on liquid chromatography/ultraviolet/14C and/or liquid chromatography/mass spectrometry methods included 25-desacetyl-rifapentine, 3-formyl-25-desacetyl-rifapentine, and 3-formyl-rifapentine. The compounds rifapentine, 25-desacetyl-rifapentine, and 3-formyl-rifapentine were present in rat bile samples. These studies show that the metabolism and disposition of rifapentine in mice, rats, and monkeys were similar.
利福喷汀是利福平的环戊基衍生物,目前正处于研发阶段,用于治疗结核分枝杆菌和鸟分枝杆菌复合群感染。这些研究旨在调查单次静脉注射和口服14C-利福喷汀在小鼠、胆管插管和未插管大鼠以及猴子体内的处置和生物转化情况。质量平衡研究包括对给药后长达120小时收集的尿液、粪便、胆汁、笼具冲洗液、尸体和笼内空气进行14C分析。使用高效液相色谱和放射性同位素检测对从尿液、胆汁和粪便中提取的放射性化合物进行分离。获得了选定色谱峰的质谱图。所有三个物种的处置结果相似。尿液中回收的14C-利福喷汀放射性剂量不到5%,这表明在这些物种中,肾脏排泄是次要的消除途径。放射性消除的主要途径是进入粪便,其中回收了超过75%的放射性。在胆管插管的大鼠中,无论是口服还是静脉给药,胆汁排泄都是放射性消除的主要途径。静脉注射或口服给药动物的粪便样本的放射色谱图相似。在小鼠和大鼠粪便样本放射色谱图中观察到10个放射性区域,在猴子粪便样本放射色谱图中观察到7个放射性区域。粪便中鉴定出的最丰富化合物通常是完整的利福喷汀(小鼠中占剂量的27%-41%,大鼠中占剂量的3%-35%,猴子中占剂量的17%-29%)。基于液相色谱/紫外/14C和/或液相色谱/质谱方法在粪便中鉴定或表征的其他峰包括25-去乙酰基利福喷汀、3-甲酰基-25-去乙酰基利福喷汀和3-甲酰基利福喷汀。利福喷汀、25-去乙酰基利福喷汀和3-甲酰基利福喷汀存在于大鼠胆汁样本中。这些研究表明,利福喷汀在小鼠、大鼠和猴子体内的代谢和处置情况相似。